|
1
|
International drug monitoring. The role of
national centers. Report of a WHO meeting. World Health Organ Tech
Rep Ser. 498:1–25. 1972.PubMed/NCBI
|
|
2
|
Bousquet PJ, Demoly P, Romano A, Aberer W,
Bircher A, Blanca M, Brockow K, Pichler W, Torres MJ, Terreehorst
I, et al: Pharmacovigilance of drug allergy and hypersensitivity
using the ENDA-DAHD database and the GALEN platform. The Galenda
project. Allergy. 64:194–203. 2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Demoly P, Adkinson NF, Brockow K, Castells
M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler
W, et al: International consensus on drug allergy. Allergy.
69:420–437. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rawlins MD and Thompson JW: Pathogenesis
of adverse drug reactions. In: Textbook of adverse reactions.
Davies DM (ed), Oxford University Press, pp44, 1977.
|
|
5
|
Thong B and Vervloet D: Drug Allergies.
WAO. Available from: https://www.worldallergy.org/education-and-programs/education/allergic-disease-resource-center/professionals/drug-allergies,
2007.
|
|
6
|
Hausmann OV, Seitz M, Villiger PM and
Pichler WJ: The complex clinical picture of side effects to
biologicals. Med Clin North Am. 94:791–804. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pichler WJ: Adverse side-effects to
biological agents. Allergy. 61:912–920. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sunthralingam G, Perry MR, Ward S, Brett
SJ, Castello-Cortes A, Brunner M D and Panoskaltsis N: Cytokine
storm in a phase 1 trial of the anti-CD28 monoclonal antibody
TGN1412. N Engl J Med. 355:1018–1028. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Vasquez EM, Fabrega AJ and Pollak R:
OKT3-induced cytokine-release syndrome: Occurrence beyond the
second dose and association with rejection severity. Transplant
Proc. 27:873–874. 1995.PubMed/NCBI
|
|
10
|
Wing M: Monoclonal antibody first dose
cytokine release syndromes-mechanisms and prediction. J
Immunotoxicol. 5:11–15. 2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cheifetz A and Mayer L: Monoclonal
antibodies, immunogenicity, and associated infusion reactions. Mt
Sinai J Med. 72:250–256. 2005.PubMed/NCBI
|
|
12
|
Shelley WB, Talanin N and Shelley ED:
Polysorbate 80 hypersensitivity. Lancet. 345:1312–1313.
1995.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Steele RH, Limaye S, Cleland B, Chow J and
Suranyi MG: Hypersensitivity reactions to the polysorbate contained
in recombinant erythropoietin and darbepoietin. Nephrology
(Carlton). 10:317–320. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Price KS and Hamilton RG: Anaphylactoid
reactions in two patients after omalizumab administration after
successful long-term therapy. Allergy Asthma Proc. 28:313–319.
2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Jover Cerdá V, Rodríguez Pacheco R,
Doménech Witek J, Marco de la Calle FM and de la Sen Fernández ML:
Immediate hypersensitivity to polyethylene glycols in unrelated
products: When standardization in the nomenclature of the
components of drugs, cosmetics, and food becomes necessary. Allergy
Asthma Clin Immunol. 15(9)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Stone CA Jr, Liu Y, Relling MV, Krantz MS,
Pratt AL, Abreo A, Hemler JA and Phillips EJ: Immediate
hypersensitivity to polyethylene glycols and polysorbates: more
common than we have recognized. J Allergy Clin Immunol Pract.
7:1533–1540.e8. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Stubenrauch K, Wessels U, Birnboeck H,
Ramirez F, Jahreis A and Schleypen J: Subset analysis of patients
experiencing clinical events of a potentially immunogenic nature in
the pivotal clinical trials of tocilizumab for rheumatoid
arthritis: Evaluation of an antidrug antibody ELISA using clinical
adverse event-driven immunogenicity testing. Clin Ther.
32:1597–1609. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Brennan PJ, Rodriguez Bouza T, Hsu FI,
Sloane DE and Castells MC: Hypersensitivity reactions to mAbs: 105
Desensitizations in 23 patients, from evaluation to treatment. J
Allergy Clin Immunol. 124:1259–1266. 2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vultaggio A, Matucci A, Nencini F, Pratesi
S, Parronchi P, Rossi O, Romagnani S and Maggi E: Anti-infliximab
IgE and non-IgE antibodies and induction of infusion-related severe
anaphylactic reactions. Allergy. 65:657–6561. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mezzano V, Giavina-Bianchi P, Picard M,
Caiado J and Castells M: Drug desensitization in the management of
allergy and anaphylaxis to chemotherapeutic agents and monoclonal
antibodies. BioDrugs. 28:133–144. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Georgitis JW, Browning MC, Steiner D and
Lorentz WB: Anaphylaxis and desensitization to the murine
monoclonal antibody used for renal graft rejection. Ann Allergy.
66:343–347. 1991.PubMed/NCBI
|
|
22
|
Proctor L, Renzulli B, Warren S and
Brecher ME: Transfusion medicine illustrated. Monoclonal
antibody-stimulated serum sickness. Transfusion.
44(955)2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Krishna M and Nadler SG: Immunogenicity to
biotherapeutics-the role of anti-drug immune complexes. Front
Immunol. 7(21)2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Han PD and Cohen RD: Managing immunogenic
responses to infliximab: Treatment implications for patients with
Crohn's disease. Drugs. 64:1767–1777. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wolbink GJ, Vis M, Lems W, Voskuyl AE, de
Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L and Dijkmans L:
Development of antiinfliximab antibodies and relationship to
clinical response in patients with rheumatoid arthritis. Arthritis
Rheum. 54:711–715. 2006.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Baert F, Noman M, Vermeire S, Van Assche
G, D' Haens G, Carbonez A and Rutgeerts P: Influence of
immunogenicity on the long-term efficacy of infliximab in Crohn's
disease. N Engl J Med. 348:601–608. 2003.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Haraoui B, Cameron L, Ouellet M and White
B: Anti-infliximab antibodies in patients with rheumatoid arthritis
who require higher doses of infliximab to achieve or maintain a
clinical response. J Rheumatol. 33:31–36. 2006.PubMed/NCBI
|
|
28
|
Vincent FB, Morand EF, Murphy K, Mackay F,
Mariette X and Marcelli C: Antidrug antibodies (ADAb) to tumour
necrosis factor (TNF)-specific neutralising agents in chronic
inflammatory diseases: A real issue, a clinical perspective. Ann
Rheum Dis. 72:165–178. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Radstake TR, Svenson M, Eijsbouts AM, van
den Hoogen FH, Enevold C, van Riel PL and Bendtzen K: Formation of
antibodies against infliximab and adalimumab strongly correlates
with functional drug levels and clinical responses in rheumatoid
arthritis. Ann Rheum Dis. 68:1739–1745. 2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Bartelds GM, Krieckaert CL, Nurmohamed MT,
van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L and
Wolbink GJ: Development of antidrug antibodies against adalimumab
and association with disease activity and treatment failure during
long-term follow-up. JAMA. 305:1460–1468. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Abdullah SE, Haigentz M Jr and Piperdi B:
Dermatologic toxicities from monoclonal antibodies and tyrosine
kinase inhibitors against EGFR: Pathophysiology and management.
Chemother Res Pract. 2012(351210)2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Rauer S, Stork L, Urbach H, Stathi A, Marx
A, Süss P, Prinz M, Brück W and Metz I: Drug reaction with
eosinophilia and systemic symptoms after daclizumab therapy.
Neurology. 91:e359–e363. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Bouman CA, van Herwaarden N, van den
Hoogen FH, Fransen J, van Vollenhoven RF, Bijlsma JW, Maas AV and
den Broeder AA: Long-term outcomes after disease activity-guided
dose reduction of TNF inhibition in rheumatoid arthritis: 3-Year
data of the DRESS study-a randomised controlled pragmatic
non-inferiority strategy trial. Ann Rheum Dis. 76:1716–1722.
2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Shah KM, Rancour EA, Al-Omari A and
Rahnama-Moghadam S: Striking enhancement at the site of radiation
for nivolumab-induced Stevens-Johnson syndrome. Dermatol Online J
24: Jun 6, 2018 (Epub ahead of print).
|
|
35
|
Salati M, Pifferi M, Baldessari C,
Bertolini F, Tomasello C, Cascinu S and Barbieri F: Stevens-Johnson
syndrome during nivolumab treatment of NSCLC. Ann Oncol.
29:283–284. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Saw S, Lee HY and Ng QS:
Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma
patients. Eur J Cancer. 81:237–239. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Demirtas S, El Aridi L, Acquitter M,
Fleuret C and Plantin P: Toxic epidermal necrolysis due to anti-PD1
treatment with fatal outcome. Ann Dermatol Venereol. 144:65–66.
2017.PubMed/NCBI View Article : Google Scholar : (In French).
|
|
38
|
Didona D, Paolino G, Garcovich S,
Caposiena Caro RD and Didona B: Successful use of etanercept in a
case of toxic epidermal necrolysis induced by rituximab. J Eur Acad
Dermatol Venereol. 30:e83–e84. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Fallon MJ and Heck JN: Fatal
Stevens-Johnson syndrome/toxic epidermal necrolysis induced by
allopurinol-rituximab-bendamustine therapy. J Oncol Pharm Pract.
21:388–392. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang CY, Khoo C, McCormack CJ, Xu W and
Pan Y: Acute localised exanthematous pustulosis secondary to
pembrolizumab. Australas J Dermatol. 58:322–323. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Maranduca MA, Branisteanu D, Serban DN,
Branisteanu DC, Stoleriu G, Manolache N and Serban IL: Synthesis
and physiological implications of melanic pigments. Oncol Lett.
17:4183–4187. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hwang SJ, Carlos G, Wakade D, Sharma R and
Fernandez-Penas P: Ipilimumab-induced acute generalized
exanthematous pustulosis in a patient with metastatic melanoma.
Melanoma Res. 26:417–420. 2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Blendea A, Georgescu CV, Ţolea I,
Brănişteanu DE and Costache A: An unusual cutaneous malignant
melanoma arised de novo: A case report. Rom J Morphol Embryol.
56:1217–1221. 2015.PubMed/NCBI
|
|
44
|
Suga H, Sugaya M, Tamaki Z, Yamamoto M,
Tada Y and Sato S: Varicella like generalized pustulosis induced by
adalimumab. Int J Dermatol. 52:890–892. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Bosanquet DC, Davies WL, May K, Harding KG
and Patel GK: Acute generalised exanthematous pustulosis following
intravitreal Ranibizumab. Int Wound J. 8:317–319. 2011.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Popa C, Leandro MJ, Cambridge G and
Edwards JC: Repeated B lymphocyte depletion with rituximab in
rheumatoid arthritis over 7 yrs. Rheumatology (Oxford). 46:626–630.
2007.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Cohen SB, Emery P, Greenwald MW, Dougados
M, Furie RA, Genovese EC, Keystone EC, Loveless JE, Burmester GR,
Cravets MW, et al: Rituximab for rheumatoid arthritis refractory to
anti-tumor necrosis factor therapy: Results of a multicenter,
randomized, double-blind, placebo-controlled, phase III trial
evaluating primary efficacy and safety at twenty-four weeks.
Arthritis Rheum. 54:2793–2806. 2006.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Koo S, Marty FM and Baden LR: Infectious
complications associated with immunomodulating biologic agents.
Infect Dis Clin North Am. 24:285–306. 2010.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Smolen JS, Keystone EC, Emery P, Breedveld
FC, Betteridge N, Burmester GR, Dougados M, Ferraccioli G, Jaeger
U, Klareskog L, et al: Consensus statement on the use of rituximab
in patients with rheumatoid arthritis. Ann Rheum Dis. 66:143–150.
2007.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Gelinck LB, Teng YK, Rimmelzwaan GF, van
den Bemt BJF, Kroon FP and van Laar JM: Poor serological responses
upon influenza vaccination in patients with rheumatoid arthritis
treated with rituximab. Ann Rheum Dis. 66:1402–1403.
2007.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Kelsey A, Chirch LM and Payette MJ:
Tuberculosis and interleukin blocking monoclonal antibodies: Is
there risk? Dermatol Online J. 24(13030/qt58j4n38m)2018.PubMed/NCBI
|
|
52
|
Ramos-Casals M, Roberto-Perez-Alvarez
Diaz-Lagares C, Cuadrado MJ and Khamashta MA: BIOGEAS Group.
Autoimmune diseases induced by biological agents: A double-edged
sword? Autoimmun Rev. 9:188–193. 2010.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Perez-Alvarez R, Pérez-de-Lis M and
Ramos-Casals M: BIOGEAS study group. Biologics-induced autoimmune
diseases. Curr Opin Rheumatol. 25:56–64. 2013.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Grange JD, Duquesne N, Roubeyrol F,
Branisteanu D, Sandon K, Fleury J, Gerard JP, Chauvel P, Pinzaru G,
Jean-Louis B and Bievelez B: Double irradiation for macroscopic
radioresistance or recurrence of melanomas of the posterior uvea:
Clinical, ballistic, therapeutic and prognostic aspects: Series of
19 cases among 462 patients. J Fr Ophtalmol. 22:1054–1063.
1999.PubMed/NCBI(In French).
|
|
55
|
Brănişteanu DE, Mihaila G, Alupoaei A,
Ciubotariu E, Cherciu M and Brănişteanu DE: Options and therapy
limits in a case of severe psoriasis. J Eur Acad Dermatol Venereol.
24(40)2010.
|
|
56
|
Khobzey K, Liskova I, Szegedi A, Pavlovsky
L, Lunder T, Kingo K, Miljković J, Péč J, Bohinc M and Hojnik M:
Effectiveness of adalimumab in the treatment of scalp and nail
affection in patients with moderate to severe plaque psoriasis in
routine clinical practice. Acta Dermatovenerol Alp Pannonica
Adriat. 26:11–14. 2017.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Brănişteanu DE, Voicu CM, Creţu A,
Dimitriu A, Luca MC and Sălăvăstru CM: Adverse reactions of
biological therapy for psoriasis. Rev Med Chir Soc Med Nat.
119:38–44. 2015.PubMed/NCBI
|
|
58
|
Lin JE, Reddy S, Shah VV and Wu JJ: A
review of neurologic complications of biologic therapy in plaque
psoriasis. Cutis. 101:57–60. 2008.PubMed/NCBI
|
|
59
|
Nakamura K, Kawasaki E, Imagawa A, Awata
T, Ikegami H, Uchigata Y, Kobayashi T, Shimada A, Nakanishi K,
Makino H, et al: Type 1 diabetes and interferon therapy: A
nationwide survey in Japan. Diabetes Care. 34:2084–2089.
2011.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Zornitzki T, Malnick S, Lysyy L and
Knobler H: Interferon therapy in hepatitis C leading to chronic
type 1 diabetes. World J Gastroenterol. 21:233–239. 2015.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Mariette X, Matucci-Cerinic M, Pavelka K,
Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds
A and Emery P: Malignancies associated with tumour necrosis factor
inhibitors in registries and prospective observational studies: A
systematic review and meta-analysis. Ann Rheum Dis. 70:1895–1904.
2011.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Askling J, Fahrbach K, Nordstrom B, Ross
S, Schmid CH and Symmons D: Cancer risk with tumor necrosis factor
alpha (TNF) inhibitors: Meta-analysis of randomized controlled
trials of adalimumab, etanercept, and infliximab using patient
level data. Pharmacoepidemiol Drug Saf. 20:119–130. 2011.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Dommasch ED, Abuabara K, Shin DB, Nguyen
J, Troxel AB and Gelfand JM: The risk of infection and malignancy
with tumor necrosis factor antagonists in adults with psoriatic
disease: A systematic review and meta-analysis of randomized
controlled trials. J Am Acad Dermatol. 64:1035–1050.
2011.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Thompson AE, Rieder SW and Pope JE: Tumor
necrosis factor therapy and the risk of serious infection and
malignancy in patients with early rheumatoid arthritis: A
meta-analysis of randomized controlled trials. Arthritis Rheum.
63:1479–1485. 2011.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Parakkal D, Sifuentes H, Semer R and
Ehrenpreis ED: Hepatosplenic T-cell lymphoma in patients receiving
TNF-α inhibitor therapy: Expanding the groups at risk. Eur J
Gastroenterol Hepatol. 23:1150–1156. 2011.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Mercer LK, Regierer AC, Mariette X, Dixon
WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich
K, et al: Spectrum of lymphomas across different drug treatment
groups in rheumatoid arthritis: A European registries collaborative
project. Ann Rheum Dis. 76:2025–2030. 2017.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Peréz-Soler R and Saltz L: Cutaneous
adverse effects with HER1/EGFR-targeted agents: Is there a silver
lining? J Clin Oncol. 23:5235–5246. 2005.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Kwon HJ, Coté TR, Cuffe MS, Kramer JM and
Braun MM: Case reports of heart failure after therapy with a tumor
necrosis factor antagonist. Ann Intern Med. 138:807–811.
2003.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Khasnis AA and Calabrese LH: Tumor
necrosis factor inhibitors and lung disease: A paradox of efficacy
and risk. Semin Arthritis Rheum. 40:147–163. 2010.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Dixon WG, Hyrich KL, Watson KD and Lunt M:
BSRBR Control Centre Consortium and Symmons DP; British Society for
Rheumatology Biologics Register. Influence of anti-TNF therapy on
mortality in patients with rheumatoid arthritis-associated
interstitial lung disease: Results from the British society for
rheumatology biologics register. Ann Rheum Dis. 69:1086–1091.
2010.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Collamer AN and Battafarano DF: Psoriatic
skin lesions induced by tumor necrosis factor antagonist therapy:
Clinical features and possible immunopathogenesis. Semin Arthritis
Rheum. 40:233–240. 2010.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Brănişteanu DE, Pintilie A, Andreş LE,
Dimitriu A, Oanţă A, Stoleriu G and Brănişteanu DC: Ethiopatogenic
hypotheses in lichen planus. Rev Med Chir Soc Med Nat Iasi.
120:770–776. 2016.PubMed/NCBI
|
|
73
|
Brănişteanu DE, Brănişteanu DC, Stoleriu
G, Ferariu D, Voicu CM, Stoica LE, Căruntu C, Boda D,
Filip-Ciubotaru FM, Dimitriu A and Radu CD: Histopathological and
clinical traps in lichen sclerosus: A case report. Rom J Morphol
Embryol. 57 (Suppl 2):S817–S823. 2016.PubMed/NCBI
|
|
74
|
Shaker MS, Wallace DV, Golden DBK,
Oppenheimer J, Bernstein JA, Campbell RL, Dinakar C, Ellis A,
Greenhawt M, Khan DA, et al: Anaphylaxis-a 2020 practice parameter
update, systematic review, and grading of recommendations,
assessment, development and evaluation (GRADE) analysis. J Allergy
Clin Immunol. 145:1082–1123. 2020.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Chung CH, Mirakhur B, Chan E, Le QT,
Berlin J, Morse M, Murphy BA, Murphy BA, Satinover SM, Hosen J,
Mauro D, et al: Cetuximab-induced anaphylaxis and IgE specific for
galactose-alpha-1,3-galactose. N Engl J Med. 358:1109–1117.
2008.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Torres MJ, Chaves P, Doña I, Blanca-López
N, Canto G, Mayorga C and Blanca M: T-cell involvement in
delayed-type hypersensitivity reactions to infliximab. J Allergy
Clin Immunol. 128:1365–1367.e1. 2011.PubMed/NCBI View Article : Google Scholar
|
|
77
|
de Las Vecillas Sánchez L, Alenazy LA,
Garcia-Neuer M and Castells MC: Drug hypersensitivity and
desensitizations: Mechanisms and new approaches. Int J Mol Sci.
18(1316)2017.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Cortellini G, Mascella F, Simoncelli M,
Lippolis D, Focherini MC, Cortellini F, Cherubini C, Gavioli B and
Ballardini G: Effective desensitization to tocilizumab in delayed
hypersensitivity reaction. Pharmacology. 102:114–116.
2018.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Quercia O, Emiliani F, Foschi FG and
Stefanini GF: Adalimumab desensitization after anaphylactic
reaction. Ann Allergy Asthma Immunol. 106:547–548. 2011.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Pruzansky JJ and Patterson R:
Desensitization of human basophils with suboptimal concentrations
of agonist. Evidence for reversible and irreversible
desensitization. Immunology. 65:443–447. 1988.PubMed/NCBI
|
|
81
|
MacGlashan D Jr and Lichtenstein LM: Basic
characteristics of human lung mast cell desensitization. J Immunol.
139:501–505. 1987.PubMed/NCBI
|
|
82
|
del Carmen Sancho M, Breslow R, Sloane D
and Castells M: Desensitization for hypersensitivity reactions to
medications. Chem Immunol Allergy. 97:217–233. 2012.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Aydogan M, Yologlu N, Gacar G, Uyan ZS,
Eser I and Karaoz E: Successful rapid rituximab desensitization in
an adolescent patient with nephrotic syndrome: Increase in number
of Treg cells after desensitization. J Allergy Clin Immunol.
132:478–480. 2013.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Macglashan D and Miura K: Loss of syk
kinase during IgE-mediated stimulation of human basophils. J
Allergy Clin Immunol. 114:1317–1324. 2004.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Görgülü B, Toprak SK and Bavbek S:
Successful desensitization to brentuximab after anaphylactic shock.
J Investig Allergol Clin Immunol. 28:352–354. 2018.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Pérez-Rodríguez E, Martínez-Tadeo JA,
Pérez-Rodríguez N, Hernández-Santana G, Callero-Viera A,
Rodríguez-Plata E and García-Robaina JC: Outcome of 490
desensitizations to chemotherapy drugs with a rapid one-solution
protocol. J Allergy Clin Immunol Pract. 6:1621–1627.e6.
2018.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Erdogan T, Yasar Bilge NS and Kasifoglu T:
Successful slow tocilizumab desensitization in a patient with adult
onset Still disease. Biologicals. 55:17–18. 2018.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Bavbek S, Kendirlinan R, Çerçi P, Altıner
S, Soyyiğit Ş, Çelebi Sözener Z, Aydın Ö and Gümüşburun R: rapid
drug desensitization with biologics: A single-center experience
with four biologics. Int Arch Allergy Immunol. 171:227–233.
2016.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Lieberman P, Nicklas RA, Randolph C,
Oppenheimer J, Bernstein D, Bernstein J, Ellis A, Golden DB,
Greenberger P, Kemp S, et al: Anaphylaxis-a practice parameter
update 2015. Ann Allergy Asthma Immunol. 115:341–384.
2015.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Madrigal-Burgaleta R, Vazquez-Revuelta P,
Marti-Garrido J, Lleonart R, Ali FR and Alvarez-Cuesta E:
Importance of diagnostics prior to desensitization in new drug
hypersensitivity: Chemotherapeutics and biologicals. Curr Treat
Options Allergy. 7:1–13. 2020.
|
|
91
|
Creţu A, Dimitriu A, Brănişteanu D and
Branişteanu DE: Erythema multiforme-etiopathogenic, clinical and
therapeutic aspects. Rev Med Chir Soc Med Nat Iasi. 119:55–61.
2015.PubMed/NCBI
|
|
92
|
Castells MC, Tennant NM, Sloane DE, Hsu
FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN,
Palis RI, et al: Hypersensitivity reactions to chemotherapy:
Outcomes and safety of rapid desensitization in 413 cases. J
Allergy Clin Immunol. 122:574–580. 2008.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Herrero T, Tornero P, Infante S, Fuentes
V, Sánchez MN, De Barrio M and Baeza ML: Diagnosis and management
of hypersensitivity reactions caused by oxaliplatin. J Investig
Allergol Clin Immunol. 16:327–330. 2006.PubMed/NCBI
|
|
94
|
Breslow RG, Caiado J and Castells MC:
Acetylsalicylic acid and montelukast block mast cell
mediator-related symptoms during rapid desensitization. Ann Allergy
Asthma Immunol. 102:155–160. 2009.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Ojaimi S, Harnett PR and Fulcher D:
Successful carboplatin desensitization by using omalizumab and
paradoxical diminution of total IgE levels. J Allergy Clin Immunol
Pract. 2:105–106. 2014.PubMed/NCBI View Article : Google Scholar
|
